This press release contains forward-looking statements including statements related to UNITY's understanding of cellular senescence and the role it plays in diseases of aging, the potential for UNITY ...

UNITY Biotechnology, Inc. reported its financial results for the first quarter of 2025, highlighting the 24-week and partial 36-week topline data from its Phase 2b ASPIRE study in diabetic macular ...

UNITY Biotechnology has appointed Federico Grossi, M.D., Ph.D., as its new chief medical officer to enhance its leadership team. Dr. Grossi, who has over 20 years of experience in biotech, previously ...

Jocasta Neuroscience, Inc., a biotechnology company developing therapeutics to address neurodegenerative diseases, today announced it has entered into a new licensing agreement with the University of ...

SOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UBX) (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases ...

(KRON) — The future of one biotech company on the Peninsula is drastically changing. Unity Biotechnology is laying off its entire workforce, the company announced Monday in a press release. The ...

The event will focus on UNITY’s ongoing Phase 2b ASPIRE study evaluating foselutoclax (UBX1325) head-to-head against aflibercept in diabetic macular edema (DME). Twenty-four-week safety and efficacy ...

Wedbush analyst Andreas Argyrides upgraded the shares of Unity Biotechnology Inc UBX from Neutral to Outperform and raised the price target from $2 to $4. Unity Biotechnology is developing ...

Unity Biotechnology has halted its clinical research operations and is transitioning into dissolution, focusing on settling remaining obligations and distributing any residual capital to stakeholders.